HealthyPhase 1NCT02936154
Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects
A Phase 1 study testing PF-06650833 in people with Healthy, run by Pfizer at 1 site in Japan.
Trial summary
The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of PF-06650833 orally administered as modified release tablets in healthy Japanese subjects. Read more about this study
- Who is it for?
- Ages 20 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- PF-06650833
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- 1 siteJapan
- Study dates
- Aug 2016to Oct 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy female subjects of non childbearing potential and/or male Japanese subjects between the ages of 20 and 55 years, inclusive.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Subject must have four Japanese grandparents who were born in Japan.
- Evidence of a personally signed and dated informed consent document.
- Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
Who cannot join
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- Smoking cigarettes with exceeding provided criteria.
- History of regular alcohol consumption exceeding provided limitations.
- Treatment with an investigational drug within a provided criteria.
Show all 21Show fewer
- Abnormal supine blood pressure.
- Abnormal pulse rate.
- Abnormal 12 lead ECG.
- History of tuberculosis.
- History of hepatitis or positive testing for HIV, hepatitis B surface antigen, hepatitis B surface antibodies, hepatitis B core antibodies, hepatitis C antibodies or syphilis.
- Any medical history of disease (ie, Gilbert's disease).
- Abnormal clinical laboratory test related to cardiac and skeletal muscle injury.
- Male subjects with partners currently pregnant; unwilling or unable to use a highly effective method of contraception
- Use of prescription or nonprescription drugs, vitaminic and dietary supplements within a specified duration.
- Blood donation exceeding a provided limitation.
- History of sensitivity to heparin or heparin induced thrombocytopenia.
- History of cancer (other than treated basal cell and squamous cell carcinoma of the skin) in the previous 5 years.
- Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
- Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality.
Trial locations and contacts
1 site in 1 country.
Japan1 site
P-one Clinic, Keikokai Medical Corporation
Hachioji-shi, Tokyo, 192-0071
About this study
Official title: A Phase 1, Double Blind (Sponsor Open), Placebo-controlled, Multiple-dose Study To Evaluate The Tolerability, Safety And Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fed Condition In Healthy Adult Japanese Subjects
The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of PF-06650833 orally administered as modified release tablets in healthy Japanese subjects.
- Conditions
- Healthy
- Being tested
- PF-06650833, placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-06650833Drug
placeboDrug
| Study group | Role | What they receive |
|---|---|---|
| 300 mg | Experimental | Not described Receives: Drug: PF-06650833 |
| placebo | Placebo comparator | Not described Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants experiencing an AE/SAE
Measured: Day 18
Secondary outcomes (13)
Maximum plasma concentration (Cmax)
Measured: Day 1 and Day 10
Area under the plasma concentration time curve for dosing interval (AUCtau)
Measured: Day 1 and Day 10
Time to peak concentration
Measured: Day 1 and Day 10
Clearance
Measured: Day 10
Volume of distribution
Measured: Day 10
Observed exposure accumulation ratio for AUCtau
Measured: Day 10
Observed exposure accumulation ratio for Cmax
Measured: Day 10
Minimum plasma concentration (Cmin)
Measured: Days 2, 4, 7 and 10
Fluctuation ratio (Cmax:Cmin)
Measured: Day 10
Mean residence time
Measured: Day 10
change from baseline in vital signs
Measured: Day 18
change form baseline in electrocardiogram (ECG) parameters
Measured: Day 18
Incidence of treatment emergent clinical laboratory abnormalities
Measured: Day 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2016 (estimated)
- Study startAug 2016
- Primary completionOct 2016
- Study completionOct 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02936154
- Sponsor's protocol ID
- B7921006
- Status last verified
- Oct 2018
- First submitted
- 8 Aug 2016
- Last updated
- 5 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Double Blind (Sponsor Open), Placebo-controlled, Multiple-dose Study To Evaluate The Tolerability, Safety And Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fed Condition In Healthy Adult Japanese Subjects
- ClinicalTrials.gov ID
- NCT02936154
- Acronym / sponsor ID
- B7921006
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Aug 2016 (actual)
- Primary completion
- Oct 2016 (actual)
- Study completion
- Oct 2016 (actual)
- First posted
- 18 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of PF-06650833 orally administered as modified release tablets in healthy Japanese subjects.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 300 mg | Experimental | Drug: PF-06650833 |
| placebo | Placebo comparator | Drug: placebo |
Who may qualify
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy female subjects of non childbearing potential and/or male Japanese subjects between the ages of 20 and 55 years, inclusive.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Subject must have four Japanese grandparents who were born in Japan.
- Evidence of a personally signed and dated informed consent document.
- Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
Key exclusion criteria (21 listed)
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- Smoking cigarettes with exceeding provided criteria.
- History of regular alcohol consumption exceeding provided limitations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-06650833 | Drug | 300 mg |
| placebo | Drug | placebo |
Primary outcome
Number of participants experiencing an AE/SAE
Time frame: Day 18
13 secondary outcomes
Maximum plasma concentration (Cmax)
Time frame: Day 1 and Day 10
Area under the plasma concentration time curve for dosing interval (AUCtau)
Time frame: Day 1 and Day 10
Time to peak concentration
Time frame: Day 1 and Day 10
Clearance
Time frame: Day 10
Volume of distribution
Time frame: Day 10
Observed exposure accumulation ratio for AUCtau
Time frame: Day 10
Observed exposure accumulation ratio for Cmax
Time frame: Day 10
Minimum plasma concentration (Cmin)
Time frame: Days 2, 4, 7 and 10
Fluctuation ratio (Cmax:Cmin)
Time frame: Day 10
Mean residence time
Time frame: Day 10
change from baseline in vital signs
Time frame: Day 18
change form baseline in electrocardiogram (ECG) parameters
Time frame: Day 18
Incidence of treatment emergent clinical laboratory abnormalities
Time frame: Day 18
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2018.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PF-06650833 in people with Healthy, run by Pfizer at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants experiencing an AE/SAE (time frame: Day 18). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2018.